Novocure

About Novocure

In 2000, Yoram Palti, our founder and professor emeritus of physiology and biophysics at the Technion — Israel Institute of Technology, sought to leverage his expertise in biophysics to develop a new way to treat solid tumor cancers that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. He set up a laboratory in his basement to explore the potential of electric fields as a treatment for solid tumors. Professor Palti founded Novocure to provide patients with a new cancer treatment based on his hypothesis, since proven, that alternating electric fields, when applied at specific frequencies, can disrupt cancer cell division and cause cancer cell death. This innovative treatment, Tumor Treating Fields, is a completely different approach to cancer therapy. “Nobody understood what I was doing,” Professor Palti said of his early development of Tumor Treating Fields. We launched Optune® – our Tumor Treating Fields delivery system for glioblastoma (GBM) – in the United States for the treatment of recurrent glioblastoma in 2011. In October 2015, we received U.S. Food and Drug Administration (FDA) approval to market and sell Optune for the treatment of adult patients with newly diagnosed GBM in combination with temozolomide. Our currently active markets include United States, Germany, Austria, Switzerland, Sweden, Israel and Japan. The science of Tumor Treating Fields has the potential to extend beyond GBM. We have six ongoing or completed phase 2 pilot trials for brain metastases, non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer, liver cancer and mesothelioma. We presented our phase 2 pilot data in pancreatic and ovarian cancers at our research and development day on Dec. 12, 2016. In 2016, we began our phase 3 pivotal trial in brain metastases originating from NSCLC. In 2017, we started our phase 3 pivotal trials in NSCLC and pancreatic cancer. In 2019, we initiated our phase 3 pivotal trial in recurrent, platinum-resistant ovarian cancer. Internationally, more than 20 institutions are studying the effects of Tumor Treating Fields in cancer treatment. Our company began with a patient-forward approach that continues to drive our mission today. With more than 19 years of research and many significant milestones, we have established ourselves as an innovator in oncology dedicated to improving the lives of cancer patients. About Us We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, Novocure has offices in Germany, Switzerland, Japan and Israel. Leadership We are dedicated to our mission of making TTFields available to all cancer patients who may benefit from it. Over a decade ago, we joined Novocure for the opportunity to make a meaningful difference in the lives of cancer patients. Establishing, building and growing an innovative company to provide patients with a new cancer treatment modality demands determination, perseverance and an unwavering focus on the scientific evidence to keep moving forward regardless of the obstacles or resistance that may be encountered. We are passionate about bringing our therapy to all patients who may benefit from it and to developing TTFields for additional solid tumor cancers. Bill Doyle, Executive Chairman Asaf Danziger, Chief Executive Officer Careers We count on the contributions of our talented team members who are committed to improving the lives of cancer patients. Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. We expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. We seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care.

Synonyms

Technologies (from Job Ads)

Hiring Locations (10 of 30)

Headquarters

Loading map...

Company Info

Legal Form: GmbH

Company Type: Public

Company Size: 251 - 500

Job Ad Metrics

Job Ads found: 1026

Job Ads per Month: 21.8

Hiring Locations: 30

Data Info